Tag: 上海夜网UC

Huawei aiming to win big with Messi

first_img LONG-TERM PARTNERSHIP BARCELONA, Spain: Huawei is the top information communication technology brand in its China-based headquarters, and an impressive third in smartphones globally. Now Kevin Ho, president, Handset Business, Huawei Consumer, feels that with international football star Lionel Messi, the brand will move from challenger to global leaders soon. The Huawei brand can be found in more than 170 countries around the world including Jamaica and the Caribbean. It is considered the largest telecommunications equipment manufacturer in the world, having overtaken Ericsson in 2012. Huawei chose Barcelona superstar Lionel Messi as their brand ambassador because his journey to becoming the best player in the world, his domination over his opponents and other inspiring qualities speak to what the brand is seeking to achieve globally. Messi is a five-time FIFA World Player of the Year. “We are seeking a long-term partnership. He is a win, win. Look to see Huawei and Messi in the future,” Ho assured, following Thursday’s announcement of Messi as their global ambassador. He believes the Messi-Huawei partnership will prove vital in helping them to overcome rivals Apple and Samsung. “He overcame physical challenges as a young footballer to become the best, and the way he dominates on the field and always helps his team win … is very inspiring to a lot of people,” Ho continued. When asked by The Sunday Gleaner if Huawei could, in the near future, look to contract Jamaican track stars like Jamaica’s Usain Bolt, Ho said for now they are happy with Messi, but will always look to grow the business. Meanwhile, Huawei is set to launch their new P9 smart phone. It is expected to be launched in London on April 6. According to Ho, five reasons why Huawei devices stand out from others are, “design, craftsmanship, user experience, long battery life and excellent camera quality.”last_img read more

North America generated the highest revenue in the protein therapeutics market

first_imgTherapeutic proteins are an important class of drugs, which serve patients in need of novel therapies. Approved recombinant protein therapeutics are developed to treat a wide array of clinical indications, including cancers, genetic disorders, infectious diseases, and metabolic disorders.The major factors that drive the growth of the global protein therapeutics market include introduction & application of new plasma-derived therapies, surge in prevalence of chronic & life-threatening diseases, and rise in awareness among populace regarding the high efficiency of protein therapeutics. However, high cost of protein therapies and complex reimbursement scenario impede the market growth. Conversely, increase in novel indications for known protein therapeutics and untapped emerging markets are anticipated to provide lucrative opportunities for the manufacturers in this industry.The metabolic disorders application generated the highest revenue of $27,837 million in 2016, and is anticipated to continue this trend in the future. This is attributed to the requirement for quality drugs and versatile therapies for disease treatment, especially diabetes. Cancer application is anticipated to grow at the highest CAGR of 8.2% from 2017 to 2023.Do Enquiry before purchasing Report @ https://www.alliedmarketresearch.com/purchase-enquiry/60?utm_source=Hitechnews&utm_medium=NiranjanNorth America held the highest market share of $72,899 million in 2016, owProtein Therapeutics Marketing to high prevalence rate of cancer and other chronic diseases, owing to rise in adoption of these drugs and increase in awareness about protein therapeutics. Asia-Pacific is expected to grow at the highest CAGR of 7.6% during the forecast period, owing to rapid industrialization in the area, increase in disposable income, and upsurge in government initiatives to modernize healthcare infrastructure.KEY FINDINGS OF THE STUDY The monoclonal antibody segment is anticipated to grow at the highest CAGR from 2017 to 2023.The cancer application segment is expected to witness the highest growth rate during the forecast period.Metabolic disease application segment is anticipated to occupy the largest share in the protein therapeutics market.North America dominated the global protein therapeutics market, and is projected to grow at a CAGR of 6.1%.The report provides extensive competitive analysis and profiles of key market players, such as Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc., and Sanofi. Other players (profiles not included in the report) in the value chain analysis include, Biogen, Inc., CSL Behring, and Genentech, Inc. Protein Therapeutics Market was valued at $140,109 million in 2016, and is projected to reach $217,591 million by 2023, growing at a CAGR of 6.5% from 2017 to 2023. The monoclonal antibodies product segment occupied the highest market share of the market in 2016.Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/60?utm_source=Hitechnews&utm_medium=Niranjanlast_img read more